You might also be interested in:

Hamburg welcomes Rotary members from across the world: 2019 Rotary International Convention in Northern Germany

Hamburg (ots) - Over the coming days, Hamburg/Germany will be transformed into "Rotary City" as more than ...

Oshima Shipbuilding and DNV GL sign strategic cooperation

Oslo (ots) - Spurred by the IMO strategy to reduce greenhouse gas (GHG) emissions, Oshima Shipbuilding and ...

All Releases
Subscribe to Jennewein Biotechnologie GmbH

04.05.2018 – 16:00

Jennewein Biotechnologie GmbH

Jennewein Biotechnologie: First clinical trial of a blend of human milk oligosaccharides emulating the human profile of infant formula

Jennewein Biotechnologie: First clinical trial of a blend of human milk oligosaccharides emulating the human profile of infant formula
  • Photo Info
  • Download

Rheinbreitbach (ots)

Jennewein Biotechnologie GmbH announces its first clinical trial of an infant formula that contains human milk oligosaccharides at the concentrations naturally found in human breast milk.

Jennewein Biotechnologie is a leading producer of complex oligosaccharides, focusing on human milk oligosaccharides (HMOs). In July 2018, Jennewein Biotechnologie will launch its first clinical trial of an infant formula containing the five most abundant neutral and acidic HMOs at their natural concentrations, closely replicating the composition of human breast milk HMOs do not provide energy for infants, but instead perform many beneficial functions such as promoting the growth of beneficial gut bacteria, blocking pathogens, and stimulating brain development. The ability of HMOs to support beneficial gut bacteria (the human gut microbiome) is important because such bacteria not only inhibit pathogens but also coordinate with the body to reduce the risk of allergies and chronic diseases such as irritable bowel syndrome and obesity later in life.

This primary purpose of the clinical trial is to confirm the nutritional suitability and tolerability of the HMO mixture for infants, which is a pre-requisite for the registration of the new product as a novel food ingredient under EU regulations (EU2015/2283). The clinical trial will be carried out in Austria, Germany, Italy and Spain.

A secondary purpose is to compare the development of the gut microbiome in infants fed on formula with and without HMOs. The gut microbiome is now a key research topic, reflecting the development of new technologies that make it easier to characterize the composition and functionality of complex microbial communities. Jennewein Biotechnologie hopes to provide their customers and partners with greater insight into the prebiotic effects of HMOs and how these contribute to a healthy gut microbiome.

"This is a major step forward in our mission to close the gap between human breast milk and infant formula" says Stefan Jennewein, CEO and founder of Jennewein Biotechnologie GmbH.

Jennewein Biotechnologie GmbH was founded in 2005 with the vision to develop new production processes for complex oligosaccharides. The company manufactures an extensive portfolio of HMO's such as for example 2'-Fucosyllactose, 3'-Fucosyllactose or Lacto-N-tetraose. These HMO's are for medical and nutritional application.

They are produced using the latest fermentation technology. The production process is based in scientific research.

Jennewein received in 2015 approval in the US (GRAS) and in 2017 novel food authorization for 2'-Fucosyllactose in the European Union.


For further information please contact Bettina Gutierrez,, +49 2224-9197346

Original content of: Jennewein Biotechnologie GmbH, transmitted by news aktuell

All Releases
Subscribe to Jennewein Biotechnologie GmbH
  • Printable version
  • PDF version

Places in this release

Topics in this relase